Enveda Raises $311M to Advance AI-Discovered Nature-Based Drugs

Enveda, a biotech startup that uses artificial intelligence to discover new drugs from plants and microbes, raises $311 million in a Series E round at a $2 billion valuation. Catalio Capital Management leads the funding, with participation from Iconiq and other investors. The new round doubles the company's valuation from just 12 months earlier.

Founded in 2019 by Viswa Colluru, an early employee of Recursion Pharmaceuticals, Enveda works on the idea that powerful medicines can be harnessed from the natural world rather than synthesized entirely in a lab. The company uses AI and other techniques to accelerate the discovery of these nature-derived drug candidates.

While AI has not yet produced any FDA-approved drugs, Enveda is part of a wave of companies moving AI-discovered candidates into human clinical trials. The startup currently tests several drugs in patients, including one targeting severe skin conditions and another designed to help maintain weight loss after patients stop taking GLP-1 medications.

Read More at the original source →